Egfr Signaling
Egfr Signaling - Related Videos
08:15
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
0 Views •
Cited by 1 •
2024
Here, we present a protocol describing network pharmacology and molecular docking techniques to explore the mechanism of action of Jiawei Shengjiang San (JWSJS) in treating diabetic nephropathy.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
0 Views •
Cited by 7 •
2021
This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.
15:05
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
0 Views •
Cited by 7 •
2020
The objective of this protocol is to use molecular dynamics simulations to examine the dynamic structural changes that occur due to activating mutations of the EGFR kinase protein.
FAQs
Growth-factor binding promotes pairing of EGFR molecules, followed by tyrosine autophosphorylation. These added phosphate groups create docking sites for intracellular signaling proteins, allowing the receptor to transmit information beyond the cell membrane. This sequence links an external growth signal to downstream programs that influence cellular growth, survival, and differentiation.
EGFR can activate both RAS-RAF-MEK-ERK and PI3K-AKT signaling, providing more than one route from receptor activation to cellular responses. Their inclusion among EGFR outputs helps explain how one membrane receptor can regulate several biological processes, including growth and survival. This pathway organization is also relevant when abnormal signaling produces complex tumor behavior.
These alterations can increase or dysregulate EGFR signaling, allowing growth-promoting and survival-related signals to remain stronger than normal. The resulting pathway activity may support tumor growth and contribute to treatment resistance. Because different abnormalities affect the receptor system in different ways, identifying them provides important context for understanding a tumor’s signaling behavior.
In normal biology, EGFR signaling contributes to development and tissue repair, processes that require controlled regulation of cell behavior. The same signaling capacity becomes harmful when receptor activity is abnormal, because growth and survival programs can become associated with cancer progression. This contrast makes EGFR a useful framework for studying both tissue maintenance and disease mechanisms.
EGFR mutations, amplifications, and overexpression can help guide the use of targeted therapies in medicine. These findings connect the molecular state of a tumor with treatment options directed at EGFR signaling, including tyrosine kinase inhibitors and therapeutic antibodies. Their clinical relevance lies in linking pathway abnormalities with a more biologically informed treatment strategy.
Both tyrosine kinase inhibitors and therapeutic antibodies are targeted approaches included in the medical study of EGFR signaling. Their use reflects the goal of addressing abnormal receptor-driven activity rather than treating tumors without regard to their signaling features. EGFR alterations and expression patterns therefore provide context for selecting and interpreting these treatment strategies.